Associated Papers
Association of CYP2B6 and OPRM1 Genotypes with Methadone Dose Requirements and Serum Concentrations in a Vietnamese Cohorts.
Nguyen QG et al.
Balkan Journal of Medical Genetics : Bjmg, 2025
Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use.
Ramli FF
Bosnian Journal of Basic Medical Sciences, 2021
Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis.
Yoon HY et al.
Scientific Reports, 2020
Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a CYP2B6*7 variant.
Ming Z et al.
Pharmacogenomics, 2019
Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.
Wang PF et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2019
Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment.
Kringen MK et al.
Therapeutic Drug Monitoring, 2017
Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study.
Tsuji D et al.
Medicine, 2016
Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes.
Gao N et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 2016
CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide.
Labib RM et al.
Plos One, 2016
PharmGKB summary: Efavirenz pathway, pharmacokinetics.
McDonagh EM et al.
Pharmacogenetics and Genomics, 2015
CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.
Manosuthi W et al.
International Journal of Antimicrobial Agents, 2014
CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.
Levran O et al.
Addiction Biology, 2013
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Manosuthi W et al.
Antimicrobial Agents and Chemotherapy, 2013
The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy.
Cabrera Figueroa S et al.
Therapeutic Drug Monitoring, 2010
OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths.
Bunten H et al.
Clinical Pharmacology and Therapeutics, 2010
Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans.
Arenaz I et al.
Fundamental & Clinical Pharmacology, 2010
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J et al.
British Journal of Cancer, 2010
Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
Robertson SM et al.
Journal of Acquired Immune Deficiency Syndromes (1999), 2008
Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?
Singh V et al.
Cancer Investigation, 2008
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M et al.
Pharmacogenetics and Genomics, 2007
Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese.
Guan S et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 2006
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz.
Wang J et al.
Pharmacogenetics and Genomics, 2006
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S et al.
Clinical Pharmacology and Therapeutics, 2005
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.
Tsuchiya K et al.
Biochemical and Biophysical Research Communications, 2004
Overview of the pharmacogenetics of HIV therapy.
Rodríguez-Nóvoa S et al.
The Pharmacogenomics Journal, 0